Iovance Biotherapeutics, Inc. (0JDK.L)
USD 2.97
(-0.1%)
USD 2.97
(-0.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 780.35 Million USD | 17.53% |
| 2022 | 663.98 Million USD | -14.58% |
| 2021 | 777.33 Million USD | 1.15% |
| 2020 | 768.45 Million USD | 122.96% |
| 2019 | 344.65 Million USD | -28.32% |
| 2018 | 480.82 Million USD | 209.46% |
| 2017 | 155.37 Million USD | -9.61% |
| 2016 | 171.88 Million USD | 62.69% |
| 2015 | 105.65 Million USD | 127.18% |
| 2014 | 46.5 Million USD | 134.01% |
| 2013 | 19.87 Million USD | 67467.57% |
| 2012 | 29.41 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 869.83 Million USD | 11.47% |
| 2024 Q2 | 964.32 Million USD | 10.86% |
| 2023 Q3 | 852.31 Million USD | 12.55% |
| 2023 Q1 | 824.76 Million USD | 24.22% |
| 2023 Q2 | 757.29 Million USD | -8.18% |
| 2023 FY | 780.35 Million USD | 17.53% |
| 2023 Q4 | 780.35 Million USD | -8.44% |
| 2022 Q4 | 663.98 Million USD | 21.63% |
| 2022 Q3 | 545.92 Million USD | -10.63% |
| 2022 Q2 | 610.87 Million USD | -12.89% |
| 2022 FY | 663.98 Million USD | -14.58% |
| 2022 Q1 | 701.25 Million USD | -9.79% |
| 2021 Q3 | 828.82 Million USD | -2.81% |
| 2021 Q4 | 777.33 Million USD | -6.21% |
| 2021 Q1 | 750.57 Million USD | -2.33% |
| 2021 FY | 777.33 Million USD | 1.15% |
| 2021 Q2 | 852.79 Million USD | 13.62% |
| 2020 Q3 | 782.29 Million USD | -4.31% |
| 2020 Q4 | 768.45 Million USD | -1.77% |
| 2020 FY | 768.45 Million USD | 122.96% |
| 2020 Q1 | 288.29 Million USD | -16.35% |
| 2020 Q2 | 817.56 Million USD | 183.58% |
| 2019 Q4 | 344.65 Million USD | -12.91% |
| 2019 Q3 | 395.74 Million USD | -9.22% |
| 2019 Q2 | 435.92 Million USD | -5.54% |
| 2019 Q1 | 461.5 Million USD | -4.02% |
| 2019 FY | 344.65 Million USD | -28.32% |
| 2018 Q4 | 480.82 Million USD | 77.53% |
| 2018 Q3 | 270.83 Million USD | -4.89% |
| 2018 Q2 | 284.75 Million USD | -7.32% |
| 2018 Q1 | 307.24 Million USD | 97.75% |
| 2018 FY | 480.82 Million USD | 209.46% |
| 2017 Q4 | 155.37 Million USD | -10.69% |
| 2017 FY | 155.37 Million USD | -9.61% |
| 2017 Q3 | 173.97 Million USD | 26.05% |
| 2017 Q1 | 155.38 Million USD | -9.6% |
| 2017 Q2 | 138.01 Million USD | -11.18% |
| 2016 Q3 | 182.32 Million USD | -5.8% |
| 2016 FY | 171.88 Million USD | 62.69% |
| 2016 Q4 | 171.88 Million USD | -5.73% |
| 2016 Q2 | 193.54 Million USD | 92.07% |
| 2016 Q1 | 100.76 Million USD | -4.62% |
| 2015 Q2 | 114.73 Million USD | 1.06% |
| 2015 FY | 105.65 Million USD | 127.18% |
| 2015 Q3 | 112.22 Million USD | -2.19% |
| 2015 Q4 | 105.65 Million USD | -5.86% |
| 2015 Q1 | 113.53 Million USD | 144.13% |
| 2014 Q3 | 17.41 Million USD | -6.03% |
| 2014 Q4 | 46.5 Million USD | 167.02% |
| 2014 Q1 | 18.08 Million USD | -9.01% |
| 2014 Q2 | 18.53 Million USD | 2.5% |
| 2014 FY | 46.5 Million USD | 134.01% |
| 2013 FY | 19.87 Million USD | 67467.57% |
| 2013 Q2 | 597.74 Thousand USD | 2009.73% |
| 2013 Q1 | 28.33 Thousand USD | -3.67% |
| 2013 Q3 | 168.62 Thousand USD | -71.79% |
| 2013 Q4 | 19.87 Million USD | 11685.64% |
| 2012 FY | 29.41 Thousand USD | 0.0% |
| 2012 Q4 | 29.41 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 6.173% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 16.729% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -0.318% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -371.5% |
| bluebird bio, Inc. | 619.16 Million USD | -26.034% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -520.094% |
| Imunon, Inc. | 21.91 Million USD | -3460.309% |
| Editas Medicine, Inc. | 499.15 Million USD | -56.335% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 97.075% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 76.745% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 34.9% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 76.0% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 44.616% |
| Verastem, Inc. | 149.71 Million USD | -421.214% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.037% |
| Waters Corporation | 4.62 Billion USD | 83.134% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.21% |
| Biogen Inc. | 26.84 Billion USD | 97.093% |
| Nektar Therapeutics | 398.03 Million USD | -96.052% |
| Perrigo Company plc | 10.8 Billion USD | 92.781% |
| Dynavax Technologies Corporation | 997.09 Million USD | 21.738% |
| Illumina, Inc. | 10.11 Billion USD | 92.282% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2660.117% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -250.71% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1087.93% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 88.594% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -372.025% |
| Evolus, Inc. | 188.99 Million USD | -312.888% |
| Adicet Bio, Inc. | 207.29 Million USD | -276.445% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -295.305% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.641% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -279.187% |
| FibroGen, Inc. | 423.52 Million USD | -84.25% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 92.75% |
| OPKO Health, Inc. | 2.01 Billion USD | 61.209% |
| Homology Medicines, Inc. | 47.05 Million USD | -1558.31% |
| Geron Corporation | 394.07 Million USD | -98.02% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 79.625% |
| Exelixis, Inc. | 2.94 Billion USD | 73.479% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -111.77% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -405.455% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 40.018% |
| Zoetis Inc. | 14.28 Billion USD | 94.538% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -32.66% |
| Abeona Therapeutics Inc. | 64 Million USD | -1119.26% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.567% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1294.754% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 73.902% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 76.096% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -25.556% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 54.978% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 25.628% |
| Insmed Incorporated | 1.32 Billion USD | 41.32% |
| TG Therapeutics, Inc. | 329.58 Million USD | -136.766% |
| Incyte Corporation | 6.78 Billion USD | 88.494% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 57.472% |